- Home
- VNOM vs LEGN Comparison
VNOM vs LEGN Comparison
Compare VNOM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNOM
- LEGN
- Stock Information
- Founded
- VNOM 2013
- LEGN 2014
- Country
- VNOM United States
- LEGN United States
- Employees
- VNOM N/A
- LEGN N/A
- Industry
- VNOM Oil & Gas Production
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VNOM Energy
- LEGN Health Care
- Exchange
- VNOM Nasdaq
- LEGN Nasdaq
- Market Cap
- VNOM 6.3B
- LEGN 6.7B
- IPO Year
- VNOM 2014
- LEGN 2020
- Fundamental
- Price
- VNOM $38.19
- LEGN N/A
- Analyst Decision
- VNOM Strong Buy
- LEGN Strong Buy
- Analyst Count
- VNOM 14
- LEGN 12
- Target Price
- VNOM $54.85
- LEGN $73.36
- AVG Volume (30 Days)
- VNOM 2.0M
- LEGN 1.1M
- Earning Date
- VNOM 11-03-2025
- LEGN 11-11-2025
- Dividend Yield
- VNOM 6.40%
- LEGN N/A
- EPS Growth
- VNOM 16.12
- LEGN N/A
- EPS
- VNOM 3.30
- LEGN N/A
- Revenue
- VNOM $932,200,000.00
- LEGN $796,838,000.00
- Revenue This Year
- VNOM $71.68
- LEGN $70.75
- Revenue Next Year
- VNOM N/A
- LEGN $52.47
- P/E Ratio
- VNOM $11.59
- LEGN N/A
- Revenue Growth
- VNOM 5.03
- LEGN 74.75
- 52 Week Low
- VNOM $34.71
- LEGN $27.34
- 52 Week High
- VNOM $56.76
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- VNOM 51.51
- LEGN 43.57
- Support Level
- VNOM N/A
- LEGN $32.70
- Resistance Level
- VNOM $39.82
- LEGN $34.71
- Average True Range (ATR)
- VNOM 1.06
- LEGN 1.20
- MACD
- VNOM -1.46
- LEGN 0.00
- Stochastic Oscillator
- VNOM 94.23
- LEGN 41.08
About VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.